Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study

This study aimed to prospectively evaluate the association between the appearance and evolution of retinopathy of prematurity (ROP) and selected blood parameters, focusing on platelets count. In total, 157 preterm consecutive babies screened for ROP were included and classified in: ROP necessitating treatment (group ROP1), ROP regressed without therapy (group ROP2) and no ROP (group no-ROP), divided in two phases for each group depending on gestational age. Blood parameters were weekly gathered and referred to postmenstrual age, ROP severity and phase. Platelet count mean values were statistically lower (p < 0.001) during both phases in ROP1 group (179 × 109/L vs. 213 × 109/L in phase 1 and 2, respectively) vs. other groups (ROP2: 286 × 109/L vs. 293 × 109/L; no ROP: 295 × 109/L vs. 313 × 109/L). Platelet count at birth <181 × 109 was statistically associated with Type 1 ROP development and evolution (sensibility = 76.47%, 95% confidence interval 60.0–87.6; specificity = 66.12%, 95% confidence interval 57.3–73.9). In ROP 1 group, a platelets count mean value “spike” (392.6 × 109/L) was documented at 36 weeks of corrected gestational age, preceding the need for treatment performed at a median of 38.1 ± 3.2 weeks. Early birth thrombocytopenia is confirmed as a biomarker of development and progression of ROP requiring treatment. The increase of platelets count at 35–37 weeks of corrected gestational age can be considered a possible clinical biomarker anticipating Type 1 ROP progression in preterm infants.

[1]  Lois E. H. Smith,et al.  Decreased Platelet Counts and Serum Levels of VEGF-A, PDGF-BB, and BDNF in Extremely Preterm Infants Developing Severe ROP , 2021, Neonatology.

[2]  S. Salvadori,et al.  Severe retinopathy of prematurity is associated with early post-natal low platelet count , 2021, Scientific reports.

[3]  W. Kuliczkowski,et al.  Platelet polyphosphate level is elevated in patients with chronic primary thrombocytopenia: A preliminary study. , 2020, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[4]  R. Flaumenhaft,et al.  Megakaryocytes package contents into separate α-granules that are differentially distributed in platelets. , 2019, Blood advances.

[5]  A. Razak,et al.  Association of small for gestational age with retinopathy of prematurity: a systematic review and meta-analysis , 2019, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[6]  Ji Woong Chang Risk factor analysis for the development and progression of retinopathy of prematurity , 2019, PloS one.

[7]  C. Gilbert,et al.  Epidemiology of ROP update - Africa is the new frontier. , 2019, Seminars in perinatology.

[8]  Lois E. H. Smith,et al.  Thrombocytopenia is associated with severe retinopathy of prematurity. , 2018, JCI insight.

[9]  Lois E. H. Smith,et al.  Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity , 2018, Pediatric Research.

[10]  K. Taylor,et al.  The genetics of retinopathy of prematurity: a model for neovascular retinal disease. , 2018, Ophthalmology. Retina.

[11]  Ryan Swan,et al.  Retinopathy of prematurity: a review of risk factors and their clinical significance. , 2018, Survey of ophthalmology.

[12]  J. Geisel,et al.  Nucleated red blood cells and serum lactate values on days 2 and 5 are associated with mortality and morbidity in VLBW infants , 2018, Wiener Medizinische Wochenschrift.

[13]  Jiayan Huang,et al.  Longitudinal study of the association between thrombocytopenia and retinopathy of prematurity. , 2018, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[14]  M. Akın,et al.  Platelet mass index can be a reliable marker in predicting the prognosis of retinopathy of prematurity in very preterm infants. , 2017, Pediatrics and neonatology.

[15]  A. L. Solebo,et al.  Epidemiology of blindness in children , 2017, Archives of Disease in Childhood.

[16]  C. Bunce,et al.  Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk , 2017, BMJ Open.

[17]  R. Bercovitz,et al.  Neonatal Platelet Transfusions and Future Areas of Research. , 2016, Transfusion medicine reviews.

[18]  Lois E. H. Smith,et al.  Aggressive Posterior Retinopathy of Prematurity Is Associated with Multiple Infectious Episodes and Thrombocytopenia , 2016, Neonatology.

[19]  R. Christensen,et al.  Thrombocytopenia in Small-for-Gestational-Age Infants , 2015, Pediatrics.

[20]  Gabrielle Lapping-Carr,et al.  Neonatal Thrombocytopenia: Etiology and Diagnosis. , 2015, Pediatric annals.

[21]  M. Hartnett,et al.  Mechanisms and management of retinopathy of prematurity. , 2012, The New England journal of medicine.

[22]  Gui-Shuang Ying,et al.  Thrombocytopenia and retinopathy of prematurity. , 2011, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[23]  G. Quinn,et al.  Retinopathy of prematurity: an epidemic in the making. , 2010, Chinese medical journal.

[24]  Anand Vinekar,et al.  DO PLATELETS HAVE A ROLE IN THE PATHOGENESIS OF AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY? , 2010, Retina.

[25]  J. Folkman,et al.  Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. , 2008, Blood.

[26]  J. Folkman Opinion: Angiogenesis: an organizing principle for drug discovery? , 2007, Nature Reviews Drug Discovery.

[27]  Anna L. Ells,et al.  The International Classification of Retinopathy of Prematurity revisited. , 2005, Archives of ophthalmology.

[28]  W. Tasman,et al.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. , 2004, Archives of ophthalmology.

[29]  W. Fierson,et al.  Screening Examination of Premature Infants for Retinopathy of Prematurity , 1997, Pediatrics.

[30]  J. Stone,et al.  Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. , 1996, Investigative ophthalmology & visual science.

[31]  B. Brüne,et al.  Receptor occupancy regulates Ca2+ entry and intracellular Ca2+ redistribution in activated human platelets. , 1994, The Biochemical journal.

[32]  N. Ashton,et al.  Effect of Oxygen on Developing Retinal Vessels with Particular Reference to the Problem of Retrolental Fibroplasia , 1954, The British journal of ophthalmology.

[33]  F. Ovalı,et al.  THROMBOCYTOPENIA AS A RISK FACTOR FOR RETINOPATHY OF PREMATURITY , 2019, Retina.

[34]  J. Flynn,et al.  A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. , 1992, The New England journal of medicine.